Threshold
Pharmaceuticals, Inc. THLD today announced that new data
from an ongoing Phase 1/2 trial evaluating TH-302 and low-dose
dexamethasone with or without the proteasome inhibitor bortezomib
(Velcade(R)) in patients with relapsed/refractory multiple myeloma
will be presented in a poster at the 56th Annual Meeting of the
American Society of Hematology (ASH) held in San Francisco,
California, from December 6 - 9, 2014 (Abstract #2142).
The poster titled, "Phase 1/2 Trial of TH-302 and Dexamethasone
without or with Bortezomib (TBorD) in Patients with
Relapsed/Refractory Multiple Myeloma" (Abstract #2142) will be
presented during Session 653 titled, "Myeloma: Therapy, e
xcluding
Transplantation: Poster I" on Saturday, December 6, 2014 from 5:30 PM
- 7:30 PM at the Moscone Center, West Building, Level 1.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in